Chemistry: molecular biology and microbiology – Enzyme separation or purification
Reexamination Certificate
2000-09-06
2002-06-18
Rotman, Alan L. (Department: 1625)
Chemistry: molecular biology and microbiology
Enzyme separation or purification
C435S816000, C546S300000, C546S301000, C546S302000
Reexamination Certificate
active
06406912
ABSTRACT:
This application is a national stage filing under 35 U.S.C. §371 of international application No. PCT/EP99/01113, filed on Feb. 20, 1999.
Process for the enzymatic separation of enantiomers of 3(R)- and 3(S)-hydroxy-1-methyl-4-(2,4,6-trimethoxyphenyl )-1,2,3,6-tetrahydropyridine or of the carboxylic acid esters.
The invention relates to a process for the preparation of optically pure compounds of the formula (I) by stereodifferentiating reaction of the mixtures of enantiomers with the aid of an enzyme.
3(S)- and 3(R)-hydroxy-1-methyl4-(2,4,6-trimethoxyphenyl)-1,2,3,6-tetrahydropyridine (compounds of the formula (I) where R═H) or their ester derivatives (compounds of the formula (I) where R═COR
1
) are central units or precursors of the synthesis of flavopiridol (HMR 1275 or L 86 8275) described in the patent application No. HMR 98/L 001 (“Process for the preparation of (−)cis-3-hydroxy-1-methyl-4(R)−(2,4,6-trimethoxy-phenyl)piperidine)”), of the first potent inhibitor of cyclin-dependent protein kinase (see, for example, Sedlacek, Hans Harald; Czech, Joerg; Naik, Ramachandra; Kaur, Gurmeet; Worland, Peter; Losiewicz, Michael; Parker, Bernard; Carlson, Bradley; Smith, Adaline; et al. Flavopiridol (L 86 8275; NSC 649890), a new kinase inhibitor for tumor therapy, Int. J. Oncol. (1996), 9(6), 1143-1168 or Czech, Joerg; Hoffmann, Dieter; Naik, Ramachandra; Sedlacek, Hans-Harald; Antitumoral activity of flavone L 86 8275. Int. J. Oncol. (1995), 6(1), 31-36).
A resolution of racemates or separation of enantiomers of the compounds of the formula (I) is not known.
It has now been found that compounds of the formula (I) can be obtained in optically pure form from the mixtures of enantiomers by enzymatic ester cleavage (hydrolysis or alcoholysis).
The present invention thus relates to a process for the kinetic resolution of racemates of compounds of the formula (I),
which comprises subjecting enantiomer mixtures or racemic mixtures of compound s of the formula (I), in which
R is COR
1
where R
1
=(C
1
-C
16
)-alkyl, (C
2
-C
16
)-alkenyl or (C
3
-C
16
)-alkynyl, C
n
H
2n
-cycloalkyl where n=1-16, which can be branched or unbranched and which can be substituted by 1-3 substituents from the group F, Cl, Br, I, CF
3
, CN, NO
2
, hydroxyl, methoxy, ethoxy and COOR
2
, where R
2
=(C
1
-C
4
)-alkyl and (C
2
-C
4
)-alkenyl, which can be branched or unbranched and which can be substituted by 1-3 substituents from the group consisting of F, Cl, Br, CF
3
,
in homogeneous or heterogeneous, aqueous, aqueous/organic or organic media in the presence of an enzyme, e.g. of a lipase or esterase, e.g. from mammalian livers or pancreases or microbial origin, such as, for example, from Candida, Pseudomonas and Aspergillus, or of a protease, e.g. from Bacillus, to a stereoselective hydrolysis or alcoholysis at a temperature of 10-80° C., if appropriate in the presence of cosolvents and of a buffer, the reaction mixture preferably containing 2-50% by weight of ester
and, after the reaction has taken place, separating the unreacted ester (compound of the formula (I) where R═COR
1
) and the alcohol formed (compound of the formula (I) where R═H)—and thus the two enantiomers.
The process according to the invention is economical, simple and rapid. The reaction does not require any equimolar amounts of optically pure auxiliaries, any expensive reagents, any disproportionately large amounts of solvent and any cost-intensive working steps. After the completion of the reaction, the separation of the products or of the enantiomers can be carried out by simple measures, e.g. by extraction.
Preferably, in the compounds of the formula (I)
R is COR
1
where R
1
=(C
1
-C
12
)-alkyl, (C
2
-C
12
)-alkenyl or (C
3
-C
12
)-alkynyl, C
n
H
2n
-cycloalkyl where n=1-12, which can be branched or unbranched and which can be substituted by 1-3 substituents from the group consisting of F, Cl, Br, CF
3
, CN, NO
2
, hydroxyl, methoxy, ethoxy and COOR
2
, where R
2
=methyl, ethyl and vinyl, which can be substituted by 1-3 substituents from the group consisting of F, Cl, CF
3
.
Particularly preferably, in the compounds of the formula (I)
R is COR
1
where R
1
=(C
1
-C
10
)-alkyl, (C
2
-C
10
)-alkenyl or (C
3
-C
10
)-alkynyl, C
n
H
2n
-cycloalkyl where n=1-10, which can be branched or unbranched and which can be substituted by 1-3 substituents from the group consisting of F, Cl, Br, CF
3
, CN, NO
2
, methoxy, and COOR
2
, where R
2
=methyl, ethyl and vinyl, which can be substituted by 1-3 substituents from the group consisting of F, Cl, CF
3
.
Very particularly preferably, in the compounds of the formula (I)
R is COR
1
where R
1
=(C
1
-C
10
)-alkyl, (C
2
-C
10
)-alkenyl or (C
3
-C
10
)-alkynyl,
which can be branched or unbranched and which can be substituted by 1-3 substituents from the group consisting of F, Cl, Br, CF
3,
and methoxy.
A procedure is preferably used in the process in which an ester of the formula (I), for example R=COR
1
where R
1
=C
3
H
7
or C
8
H
17
, is treated with a lipase, esterase or protease in a water- or alcohol-containing solution and stirred. It may be advantageous to buffer the solution mentioned, e.g. with phosphate or TRIS [=tris(hydroxymethyl)-methylamine] buffer. The addition can be, for example, 0.01-1.0 molar. A suitable buffer range is pH 5-9.
It may furthermore be advantageous to add cosolvents. Suitable cosolvents are, for example, dimethoxyethane, acetone, THF, dioxane, hexane, tert-butyl methyl ether and tert-butanol. The proportion of cosolvents in the solution is preferably 10-80%.
The enzymes employed are preferably lipases and esterases, such as, for example, cholesterol esterase (EC 3.1.1.13) from bovine pancreas (Sigma Chemical Co.), porcine liver esterase (PLE, Sigma Chemical Co.), pancreatin (Fluka and Sigma Chemical Co.), pancreas acetone powder from cattle (Sigma Chemical Co.), liver acetone powder from horses (Sigma Chemical Co.) and lipase from porcine pancreas (PPL, Sigma Chemical Co.), lipase OF from Candida rugosa (Meito Sangyo) and lipase AP-6 from Aspergillus niger (Amano Pharmaceuticals).
Each of the enzymes mentioned can be employed in free or in immobilized form (Immobilized Biocatalysts, W. Hartmeier, Springer Verlag Berlin, 1988). The amount of enzyme is freely selected depending on the reaction rate or on the reaction time desired and on the nature of the enzyme (e.g. free or immobilized) and is easy to determine by simple preliminary experiments.
The reaction mixture preferably contains 2-50% by weight of ester, particularly preferably 5-20%. The reaction temperature is 10-80° C., preferably 20-60° C., particularly preferably 20-40 ° C.
The preparation of the esters (compounds of the formula (I) where R=COR
1
) is expediently carried out from the alcohol (compound of the formula I where R=H) according to known methods of esterification (Haslam, Tetrahedron 1980, 36, 2409; Höfle, Steglich, Vorbrüggen, Angew. Chem. 1978, 90, 602) or as described in the patent application HMR 98/L 001 (“Process for the preparation of (−)cis-3-hydroxy-1-methyl-4(R)-(2,4,6-trimethoxyphenyl)piperidine”).
The products resulting from or remaining in the process can be separated in a simple manner, e.g. by extraction or chromatographic methods. The remaining ester is obtained, for example, by partitioning the reaction solution between water and n-heptane and concentrating the organic phase. The resulting alcohol can then be extracted from the aqueous phase with ethyl acetate. The enzyme can be recovered by freeze-drying. The separation (and, if appropriate, later reuse) of the enzyme can be facilitated by immobilization.
By means of suitable conduct of the reaction, it is always possible to obtain at least one enantiomer optically pure. If optically pure ester is desired, the conversion should be over (or equal to) 50%, if optically pure alcohol is desired, the conversion should be smaller (or equal to) 50%. The conversion of the enzymatic hydrol
Aventis Pharma Deutshland GmbH
Finnegan Henderson Farabow Garrett & Dunner LLP
LandOfFree
Method for enzymatic enantiomer-separation of 3(r)- and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for enzymatic enantiomer-separation of 3(r)- and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for enzymatic enantiomer-separation of 3(r)- and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2955256